Global Biologics Market - 2025 -2033
Global Biologics Market: Industry Outlook
The global biologics market reached US$ 472.71 billion in 2023, with a rise of US$ 512.25 billion in 2024, and is expected to reach US$ 966.98 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.
The global biologics market is experiencing significant growth due to the increasing burden of chronic and rare diseases, targeted therapies, and biotechnology advancements. Key players include monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies. Despite challenges like high development costs and stringent regulatory requirements, the market is poised for significant growth in the biosimilars sector and personalized medicine. Major pharmaceutical and biotech companies are investing heavily in R&D, making the biologics market a cornerstone of modern therapeutics.
Global Biologics Market Dynamics: Drivers & Restraints
Driver: Rising Prevalence of Chronic and Rare Diseases
The global biologics market is growing due to the increasing prevalence of chronic and rare diseases, such as cancer, autoimmune disorders, diabetes, and rare genetic conditions. These conditions require advanced treatment options that traditional small-molecule drugs cannot. Biologics, including monoclonal antibodies, recombinant proteins, and gene and cell therapies, offer high specificity, improved efficacy, and reduced side effects compared to conventional therapies. This growing patient population accelerates innovation in biologics development and encourages healthcare systems and biopharma companies to invest in expanding access and availability.
For instance, the US has 129 million people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases. Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, accounting for 90% of annual $4.1 trillion expenditure.
Restraint: High Cost of Biologics Development and Treatment
The global biologics market faces significant challenges due to the high cost of development and treatment. Developing biologics is more expensive than conventional small-molecule drugs, with R&D costs often exceeding USD 1.2-2.5 billion. Treatments are among the most expensive therapies available, with monoclonal antibodies and gene therapies costing patients between USD 15,000-200,000 annually. Advanced cell and gene therapies can cost over USD 2 million per dose. These high costs restrict widespread adoption, especially in low- and middle-income countries, and put pressure on payers and healthcare systems to balance innovation with affordability.
Global Biologics Market Segment Analysis
The global biologics market is segmented based on product type, application, manufacturing, end user, and region.
Product Type:
The monoclonal antibodies (mAbs) from the product type segment the expected to have 35.03% of the biologics market share.
Monoclonal Antibodies (mAbs) are a rapidly growing segment in the global biologics market due to their high therapeutic efficacy, precision targeting, and expanding indications across various diseases. The increasing prevalence of cancer, autoimmune disorders, and infectious diseases has driven demand for mAbs, offering targeted mechanisms with fewer off-target effects. Advancements in antibody engineering, strong R&D investments, regulatory approvals, and the availability of biosimilar antibodies support market growth, making mAbs a cornerstone of modern therapeutics and a primary revenue driver in the biologics market.
For instance, in June 2025, Bio-Techne Corporation has signed a distribution agreement with the U.S. Pharmacopeia, allowing the company to sell USP monoclonal antibody and recombinant AAV reference standards alongside its analytical solutions, including the Maurice system, for worldwide monoclonal antibody and gene therapy development.
Global Biologics Market - Geographical Analysis
The North America global biologics market was valued at 42.1% market share in 2024
The North American biologics market is fueled by robust healthcare infrastructure, high healthcare spending, and early adoption of advanced therapies. The US, with leading biopharmaceutical companies and research institutions, drives innovation in monoclonal antibodies, cell therapies, and gene therapies. The FDA's favorable regulatory support and accelerated approval pathways for breakthrough biologics further strengthen market growth.
For instance, in June 2025, UCB invested in a new biologics manufacturing facility in the US, serving its growing number of patients and generating an estimated $5 billion economic impact. The company is also expanding its partnerships with US CMOs to ensure support for growth drivers and future pipeline production.
Moreover, the rising prevalence of chronic conditions and demand for personalized medicine also boost biologics uptake. High awareness among physicians and patients and growing biosimilar penetration contribute to the region's global biologics market leadership.
Global Biologics Market – Major Players
The major players in the biologics market include Roche, Merck & Co., AbbVie, Pfizer, AstraZeneca, Sanofi, Johnson & Johnson’s, Bristol-Myers Squibb, Novartis, and Eli Lilly and among others.
Key Developments
The global biologics market reached US$ 472.71 billion in 2023, with a rise of US$ 512.25 billion in 2024, and is expected to reach US$ 966.98 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.
The global biologics market is experiencing significant growth due to the increasing burden of chronic and rare diseases, targeted therapies, and biotechnology advancements. Key players include monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies. Despite challenges like high development costs and stringent regulatory requirements, the market is poised for significant growth in the biosimilars sector and personalized medicine. Major pharmaceutical and biotech companies are investing heavily in R&D, making the biologics market a cornerstone of modern therapeutics.
Global Biologics Market Dynamics: Drivers & Restraints
Driver: Rising Prevalence of Chronic and Rare Diseases
The global biologics market is growing due to the increasing prevalence of chronic and rare diseases, such as cancer, autoimmune disorders, diabetes, and rare genetic conditions. These conditions require advanced treatment options that traditional small-molecule drugs cannot. Biologics, including monoclonal antibodies, recombinant proteins, and gene and cell therapies, offer high specificity, improved efficacy, and reduced side effects compared to conventional therapies. This growing patient population accelerates innovation in biologics development and encourages healthcare systems and biopharma companies to invest in expanding access and availability.
For instance, the US has 129 million people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases. Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, accounting for 90% of annual $4.1 trillion expenditure.
Restraint: High Cost of Biologics Development and Treatment
The global biologics market faces significant challenges due to the high cost of development and treatment. Developing biologics is more expensive than conventional small-molecule drugs, with R&D costs often exceeding USD 1.2-2.5 billion. Treatments are among the most expensive therapies available, with monoclonal antibodies and gene therapies costing patients between USD 15,000-200,000 annually. Advanced cell and gene therapies can cost over USD 2 million per dose. These high costs restrict widespread adoption, especially in low- and middle-income countries, and put pressure on payers and healthcare systems to balance innovation with affordability.
Global Biologics Market Segment Analysis
The global biologics market is segmented based on product type, application, manufacturing, end user, and region.
Product Type:
The monoclonal antibodies (mAbs) from the product type segment the expected to have 35.03% of the biologics market share.
Monoclonal Antibodies (mAbs) are a rapidly growing segment in the global biologics market due to their high therapeutic efficacy, precision targeting, and expanding indications across various diseases. The increasing prevalence of cancer, autoimmune disorders, and infectious diseases has driven demand for mAbs, offering targeted mechanisms with fewer off-target effects. Advancements in antibody engineering, strong R&D investments, regulatory approvals, and the availability of biosimilar antibodies support market growth, making mAbs a cornerstone of modern therapeutics and a primary revenue driver in the biologics market.
For instance, in June 2025, Bio-Techne Corporation has signed a distribution agreement with the U.S. Pharmacopeia, allowing the company to sell USP monoclonal antibody and recombinant AAV reference standards alongside its analytical solutions, including the Maurice system, for worldwide monoclonal antibody and gene therapy development.
Global Biologics Market - Geographical Analysis
The North America global biologics market was valued at 42.1% market share in 2024
The North American biologics market is fueled by robust healthcare infrastructure, high healthcare spending, and early adoption of advanced therapies. The US, with leading biopharmaceutical companies and research institutions, drives innovation in monoclonal antibodies, cell therapies, and gene therapies. The FDA's favorable regulatory support and accelerated approval pathways for breakthrough biologics further strengthen market growth.
For instance, in June 2025, UCB invested in a new biologics manufacturing facility in the US, serving its growing number of patients and generating an estimated $5 billion economic impact. The company is also expanding its partnerships with US CMOs to ensure support for growth drivers and future pipeline production.
Moreover, the rising prevalence of chronic conditions and demand for personalized medicine also boost biologics uptake. High awareness among physicians and patients and growing biosimilar penetration contribute to the region's global biologics market leadership.
Global Biologics Market – Major Players
The major players in the biologics market include Roche, Merck & Co., AbbVie, Pfizer, AstraZeneca, Sanofi, Johnson & Johnson’s, Bristol-Myers Squibb, Novartis, and Eli Lilly and among others.
Key Developments
- In June 2025, WuXi Biologics has launched WuXiHigh 2.0, a high-throughput formulation development platform for high concentration biologics, capable of achieving protein concentrations of up to 230 mg/mL and achieving viscosity reduction of up to 90%.
- In May 2024, Commit Biologics, a stealth company, raised €16 million ($17.2 million) to develop antibody therapies for cancer and autoimmune diseases using their bispecific complement engaging (BiCE) technology, with primary investors being Novo Nordisk's holding and investment business, Novo Holdings, and European venture capital firm Bioqube Ventures.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by Manufacturing
2.6. Snippet by End User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Chronic and Rare Diseases
3.1.1.2. Increasing Adoption of Targeted Therapies (mAbs, cell & gene therapies)
3.1.2. Restraints
3.1.2.1. High Cost of Biologics Development and Treatment
3.1.2.2. Stringent Regulatory Approval Process
3.1.3. Opportunity
3.1.3.1. Expanding Biosimilars Market
3.1.3.2. Growing R&D in Personalized Medicine and Advanced Therapies
3.1.4. Impact Analysis
4. GLOBAL BIOLOGICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Product Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL BIOLOGICS MARKET: BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Monoclonal Antibodies (mAbs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Vaccines
5.4. Recombinant Hormones/Proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Antisense & RNAi Therapeutics
5.8. Others
6. GLOBAL BIOLOGICS MARKET: BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Infectious Diseases
6.5. Cardiovascular Disorders
6.6. Neurological Disorders
6.7. Metabolic Disorders
6.8. Others
7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
7.1.2. Market Attractiveness Index, By Manufacturing
7.2. In-house Manufacturing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Outsourced/Contract Manufacturing
8. GLOBAL BIOLOGICS MARKET: BY END USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Pharmaceutical and Biotechnology Companies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hospitals
8.4. Research & Academic Institutes
8.5. Others
9. GLOBAL BIOLOGICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Roche*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. Merck & Co.
11.3. AbbVie
11.4. Pfizer
11.5. AstraZeneca
11.6. Sanofi
11.7. Johnson & Johnson’s
11.8. Bristol-Myers Squibb
11.9. Novartis
11.10. Eli Lilly (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Applications
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by Manufacturing
2.6. Snippet by End User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Chronic and Rare Diseases
3.1.1.2. Increasing Adoption of Targeted Therapies (mAbs, cell & gene therapies)
3.1.2. Restraints
3.1.2.1. High Cost of Biologics Development and Treatment
3.1.2.2. Stringent Regulatory Approval Process
3.1.3. Opportunity
3.1.3.1. Expanding Biosimilars Market
3.1.3.2. Growing R&D in Personalized Medicine and Advanced Therapies
3.1.4. Impact Analysis
4. GLOBAL BIOLOGICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Product Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL BIOLOGICS MARKET: BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Monoclonal Antibodies (mAbs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Vaccines
5.4. Recombinant Hormones/Proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Antisense & RNAi Therapeutics
5.8. Others
6. GLOBAL BIOLOGICS MARKET: BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Infectious Diseases
6.5. Cardiovascular Disorders
6.6. Neurological Disorders
6.7. Metabolic Disorders
6.8. Others
7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
7.1.2. Market Attractiveness Index, By Manufacturing
7.2. In-house Manufacturing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Outsourced/Contract Manufacturing
8. GLOBAL BIOLOGICS MARKET: BY END USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Pharmaceutical and Biotechnology Companies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hospitals
8.4. Research & Academic Institutes
8.5. Others
9. GLOBAL BIOLOGICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Roche*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. Merck & Co.
11.3. AbbVie
11.4. Pfizer
11.5. AstraZeneca
11.6. Sanofi
11.7. Johnson & Johnson’s
11.8. Bristol-Myers Squibb
11.9. Novartis
11.10. Eli Lilly (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Applications
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Biologics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biologics Market Value, By Manufacturing, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biologics Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Biologics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 10 Global Biologics Market Value, By Manufacturing, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 12 Global Biologics Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Biologics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 North America Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 19 North America Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 23 Europe Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 24 Europe Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 Europe Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 33 South America Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 34 South America Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 South America Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Roche: Overview
Table 42 Roche: Product Portfolio
Table 43 Roche: Key Developments
Table 44 Merck & Co.: Overview
Table 45 Merck & Co.: Product Portfolio
Table 46 Merck & Co.: Key Developments
Table 47 AbbVie: Overview
Table 48 AbbVie: Product Portfolio
Table 49 AbbVie: Key Developments
Table 50 Pfizer: Overview
Table 51 Pfizer: Product Portfolio
Table 52 Pfizer: Key Developments
Table 53 AstraZeneca: Overview
Table 54 AstraZeneca: Product Portfolio
Table 55 AstraZeneca: Key Developments
Table 56 Sanofi: Overview
Table 57 Sanofi: Product Portfolio
Table 58 Sanofi: Key Developments
Table 59 Johnson & Johnson’s: Overview
Table 60 Johnson & Johnson’s: Product Portfolio
Table 61 Johnson & Johnson’s: Key Developments
Table 62 Bristol-Myers Squibb: Overview
Table 63 Bristol-Myers Squibb: Product Portfolio
Table 64 Bristol-Myers Squibb: Key Developments
Table 65 Novartis: Overview
Table 66 Novartis: Product Portfolio
Table 67 Novartis: Key Developments
Table 68 Eli Lilly: Overview
Table 69 Eli Lilly: Product Portfolio
Table 70 Eli Lilly: Key Developments
Table 1 Global Biologics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biologics Market Value, By Manufacturing, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biologics Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Biologics Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Biologics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 10 Global Biologics Market Value, By Manufacturing, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 12 Global Biologics Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Biologics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Biologics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 North America Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 19 North America Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 23 Europe Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 24 Europe Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 Europe Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 33 South America Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 34 South America Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 South America Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Biologics Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Biologics Market Value, By Application, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Biologics Market Value, By Manufacturing, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Biologics Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Biologics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Roche: Overview
Table 42 Roche: Product Portfolio
Table 43 Roche: Key Developments
Table 44 Merck & Co.: Overview
Table 45 Merck & Co.: Product Portfolio
Table 46 Merck & Co.: Key Developments
Table 47 AbbVie: Overview
Table 48 AbbVie: Product Portfolio
Table 49 AbbVie: Key Developments
Table 50 Pfizer: Overview
Table 51 Pfizer: Product Portfolio
Table 52 Pfizer: Key Developments
Table 53 AstraZeneca: Overview
Table 54 AstraZeneca: Product Portfolio
Table 55 AstraZeneca: Key Developments
Table 56 Sanofi: Overview
Table 57 Sanofi: Product Portfolio
Table 58 Sanofi: Key Developments
Table 59 Johnson & Johnson’s: Overview
Table 60 Johnson & Johnson’s: Product Portfolio
Table 61 Johnson & Johnson’s: Key Developments
Table 62 Bristol-Myers Squibb: Overview
Table 63 Bristol-Myers Squibb: Product Portfolio
Table 64 Bristol-Myers Squibb: Key Developments
Table 65 Novartis: Overview
Table 66 Novartis: Product Portfolio
Table 67 Novartis: Key Developments
Table 68 Eli Lilly: Overview
Table 69 Eli Lilly: Product Portfolio
Table 70 Eli Lilly: Key Developments
LIST OF FIGURES
Figure 1 Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 4 Global Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 5 Global Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Biologics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Biologics Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Monoclonal Antibodies (mAbs) Biologics Market Value, 2022-2033 (US$ Billion)
Figure 9 Vaccines Biologics Market Value, 2022-2033 (US$ Billion)
Figure 10 Recombinant Hormones/Proteins Biologics Market Value, 2022-2033 (US$ Billion)
Figure 11 Cell Therapy Biologics Market Value, 2022-2033 (US$ Billion)
Figure 12 Gene Therapy Biologics Market Value, 2022-2033 (US$ Billion)
Figure 13 Antisense & RNAi Therapeutics Biologics Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Biologics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Biologics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 16 Oncology Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 17 Autoimmune Diseases Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 18 Infectious Diseases Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 19 Cardiovascular Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 20 Neurological Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 21 Metabolic Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 22 Others Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 23 Global Biologics Market Y-o-Y Growth, By Manufacturing, 2023-2033 (%)
Figure 24 In-house Manufacturing Manufacturing in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 25 Outsourced/Contract Manufacturing Manufacturing in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Biologics Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 27 Pharmaceutical and Biotechnology Companies End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 28 Hospitals End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 29 Research & Academic Institutes End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 30 Others End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 31 Global Biologics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 32 North America Biologics Market Value, 2022-2033 (US$ Billion)
Figure 33 North America Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 34 North America Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 35 North America Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 36 North America Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 37 North America Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 38 Europe Biologics Market Value, 2022-2033 (US$ Billion)
Figure 39 Europe Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 40 Europe Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 41 Europe Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 42 Europe Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 43 Europe Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 44 Asia-Pacific Biologics Market Value, 2022-2033 (US$ Billion)
Figure 45 Asia-Pacific Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 47 Asia-Pacific Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 48 Asia-Pacific Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 49 Asia-Pacific Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 50 South America Biologics Market Value, 2022-2033 (US$ Billion)
Figure 51 South America Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 South America Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 53 South America Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 54 South America Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 55 South America Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 56 Middle East and Africa Biologics Market Value, 2022-2033 (US$ Billion)
Figure 57 Middle East and Africa Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 58 Middle East and Africa Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 59 Middle East and Africa Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 60 Middle East and Africa Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 61 Roche: Financials
Figure 62 Merck & Co.: Financials
Figure 63 AbbVie: Financials
Figure 64 Pfizer: Financials
Figure 65 AstraZeneca: Financials
Figure 66 Sanofi: Financials
Figure 67 Johnson & Johnson’s: Financials
Figure 68 Bristol-Myers Squibb: Financials
Figure 69 Novartis: Financials
Figure 70 Eli Lilly: Financials
Figure 1 Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 4 Global Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 5 Global Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Biologics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Biologics Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Monoclonal Antibodies (mAbs) Biologics Market Value, 2022-2033 (US$ Billion)
Figure 9 Vaccines Biologics Market Value, 2022-2033 (US$ Billion)
Figure 10 Recombinant Hormones/Proteins Biologics Market Value, 2022-2033 (US$ Billion)
Figure 11 Cell Therapy Biologics Market Value, 2022-2033 (US$ Billion)
Figure 12 Gene Therapy Biologics Market Value, 2022-2033 (US$ Billion)
Figure 13 Antisense & RNAi Therapeutics Biologics Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Biologics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Biologics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 16 Oncology Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 17 Autoimmune Diseases Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 18 Infectious Diseases Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 19 Cardiovascular Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 20 Neurological Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 21 Metabolic Disorders Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 22 Others Application in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 23 Global Biologics Market Y-o-Y Growth, By Manufacturing, 2023-2033 (%)
Figure 24 In-house Manufacturing Manufacturing in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 25 Outsourced/Contract Manufacturing Manufacturing in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Biologics Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 27 Pharmaceutical and Biotechnology Companies End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 28 Hospitals End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 29 Research & Academic Institutes End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 30 Others End User in Global Biologics Market Value, 2022-2033 (US$ Billion)
Figure 31 Global Biologics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 32 North America Biologics Market Value, 2022-2033 (US$ Billion)
Figure 33 North America Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 34 North America Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 35 North America Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 36 North America Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 37 North America Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 38 Europe Biologics Market Value, 2022-2033 (US$ Billion)
Figure 39 Europe Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 40 Europe Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 41 Europe Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 42 Europe Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 43 Europe Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 44 Asia-Pacific Biologics Market Value, 2022-2033 (US$ Billion)
Figure 45 Asia-Pacific Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 47 Asia-Pacific Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 48 Asia-Pacific Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 49 Asia-Pacific Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 50 South America Biologics Market Value, 2022-2033 (US$ Billion)
Figure 51 South America Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 South America Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 53 South America Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 54 South America Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 55 South America Biologics Market Share, By Country, 2024 & 2033 (%)
Figure 56 Middle East and Africa Biologics Market Value, 2022-2033 (US$ Billion)
Figure 57 Middle East and Africa Biologics Market Share, By Product Type, 2024 & 2033 (%)
Figure 58 Middle East and Africa Biologics Market Share, By Application, 2024 & 2033 (%)
Figure 59 Middle East and Africa Biologics Market Share, By Manufacturing, 2024 & 2033 (%)
Figure 60 Middle East and Africa Biologics Market Share, By End User, 2024 & 2033 (%)
Figure 61 Roche: Financials
Figure 62 Merck & Co.: Financials
Figure 63 AbbVie: Financials
Figure 64 Pfizer: Financials
Figure 65 AstraZeneca: Financials
Figure 66 Sanofi: Financials
Figure 67 Johnson & Johnson’s: Financials
Figure 68 Bristol-Myers Squibb: Financials
Figure 69 Novartis: Financials
Figure 70 Eli Lilly: Financials
